Evidence map›Paper›PMID 42751532›Full record

ArticleJournal of pharmaceutical analysis2026

One-pot synthesis of Mn/Fe bimetal-doped metal-organic framework as multifunctional nanocarriers for esophageal cancer targeted therapy.

Jia Ma, Xin Zhang, Xiangpeng Meng, Yuhang Dai, Huaiyong Wang, Milad Ashrafizadeh, João Conde, Zhenggang Li, Enyang Yao, Wei He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jia MaDepartment of Gastroenterology, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110032, China.
Xin ZhangDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Xiangpeng MengDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Yuhang DaiDepartment of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Huaiyong WangDepartment of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Milad AshrafizadehDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250000, China.
João CondeComprehensive Health Research Centre, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade Nova de Lisboa, Lisboa, 1169, Portugal.
Zhenggang LiDepartment of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Enyang YaoDepartment of Orthopedics, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Wei HeDepartment of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemodynamic therapy (CDT) offers new opportunities to eliminate cancer by killing tumor cells through the production of toxic hydroxyl radicals (·OH) in the tumor region. However, the efficiency of CDT is severely hampered by insufficient levels of hydrogen peroxide and large amounts of glutathione (GSH) in tumor cells. To address this issue, we developed Mn/Fe bimetallic metal-organic framework (MnFe-MOF) nanocarriers that could respond to acidic and GSH-rich conditions for loading ursolic acid (UA) and MTH1 siRNA (siMTH1), followed by surface modification with hyaluronic acid (HA). Finally, a nanoparticle named UA/siMTH1@MnFe-MOF@HA was developed for the treatment of esophageal cancer. Benefiting from HA-coated encapsulation, UA/siMTH1@MnFe-MOF@HA achieved Kyse-30 cell targeting and slow release of UA/siMTH1. The Mn/Fe ions doped in the nanoframework catalyzed the Fenton reaction in the tumor microenvironment with acidic pH and overexpression of GSH to promote reactive oxygen species (ROS) generation, and further amplified oxidative stress by consuming GSH, resulting in cell damage. Moreover, siMTH1 released by the nanoparticles can cause DNA damage and induce cellular senescence to kill cancer cells, while the released UA can induce G1 cell cycle arrest to inhibit cell proliferation, synergistically enhancing the therapeutic effect. UA/siMTH1@MnFe-MOF@HA exhibited outstanding tumor suppression

Indexed as

Chemodynamic therapyEsophageal cancerMetal ionNanoparticle

Identifiers

PMID42751532
PMCPMC13580062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.